Total Payments
$9,369
2023 Payments
$6,695
Companies
3
Transactions
15
Medicare Patients
2,531
Medicare Billing
$258,529
Payment Breakdown by Category
Consulting$4,725 (50.4%)
Research$2,169 (23.1%)
Travel$2,142 (22.9%)
Food & Beverage$333.83 (3.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $4,725 | 1 | 50.4% |
| Unspecified | $2,169 | 5 | 23.1% |
| Travel and Lodging | $2,142 | 6 | 22.9% |
| Food and Beverage | $333.83 | 3 | 3.6% |
Payments by Type
General
$7,200
10 transactions
Research
$2,169
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $8,206 | 9 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $1,124 | 5 | $0 (2018) |
| Eisai Inc. | $40.00 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $6,695 | 7 | Eli Lilly and Company ($6,655) |
| 2022 | $851.00 | 1 | Eli Lilly and Company ($851.00) |
| 2021 | $72.00 | 1 | Eli Lilly and Company ($72.00) |
| 2020 | $627.94 | 1 | Eli Lilly and Company ($627.94) |
| 2018 | $119.51 | 1 | Novartis Pharmaceuticals Corporation ($119.51) |
| 2017 | $1,004 | 4 | Novartis Pharmaceuticals Corporation ($1,004) |
All Payment Transactions
15 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/25/2023 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | Cash or cash equivalent | $40.00 | General |
| Category: Neurology | ||||||
| 07/11/2023 | Eli Lilly and Company | — | — | In-kind items and services | $153.00 | Research |
| Study: ASSESSMENT OF SAFETY AND EFFICACY OF SUBCUTANEOUS REMTERNETUG IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | ||||||
| 04/25/2023 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $4,725.00 | General |
| 02/25/2023 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $846.54 | General |
| 02/25/2023 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $298.86 | General |
| 02/25/2023 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $166.25 | General |
| 01/31/2023 | Eli Lilly and Company | — | — | In-kind items and services | $465.00 | Research |
| Study: A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | ||||||
| 01/20/2022 | Eli Lilly and Company | — | — | In-kind items and services | $851.00 | Research |
| Study: ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | ||||||
| 06/30/2021 | Eli Lilly and Company | — | — | In-kind items and services | $72.00 | Research |
| Study: ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | ||||||
| 10/15/2020 | Eli Lilly and Company | — | — | In-kind items and services | $627.94 | Research |
| Study: ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | ||||||
| 07/12/2018 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $119.51 | General |
| 06/07/2017 | Novartis Pharmaceuticals Corporation | CNP520 (Drug) | Travel and Lodging | In-kind items and services | $409.50 | General |
| 06/07/2017 | Novartis Pharmaceuticals Corporation | CNP520 (Drug) | Food and Beverage | In-kind items and services | $174.32 | General |
| 06/07/2017 | Novartis Pharmaceuticals Corporation | CNP520 (Drug) | Travel and Lodging | Cash or cash equivalent | $17.47 | General |
| 06/06/2017 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $403.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $1,551 | 3 |
| A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | Eli Lilly and Company | $465.00 | 1 |
| ASSESSMENT OF SAFETY AND EFFICACY OF SUBCUTANEOUS REMTERNETUG IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | Eli Lilly and Company | $153.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 653 | 712 | $178,022 | $68,165 |
| 2022 | 7 | 623 | 659 | $131,459 | $61,094 |
| 2021 | 7 | 644 | 707 | $149,041 | $70,642 |
| 2020 | 7 | 611 | 642 | $157,963 | $58,629 |
Total Patients
2,531
Total Services
2,720
Medicare Billing
$258,529
Procedure Codes
29
All Medicare Procedures & Services
29 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 281 | 325 | $86,536 | $35,294 | 40.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 93 | 93 | $39,875 | $12,474 | 31.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 146 | 156 | $26,103 | $11,495 | 44.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 50 | 50 | $16,243 | $4,695 | 28.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 70 | 75 | $7,115 | $3,448 | 48.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2023 | 13 | 13 | $2,150 | $758.89 | 35.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 228 | 246 | $54,120 | $27,234 | 50.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 86 | 86 | $30,665 | $11,554 | 37.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 145 | 157 | $22,115 | $11,413 | 51.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 49 | 49 | $12,985 | $5,141 | 39.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 76 | 82 | $7,626 | $4,087 | 53.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2022 | 25 | 25 | $3,500 | $1,412 | 40.4% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Facility | 2022 | 14 | 14 | $448.00 | $253.15 | 56.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 263 | 308 | $67,760 | $35,439 | 52.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 107 | 107 | $37,985 | $15,118 | 39.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 120 | 133 | $18,870 | $9,067 | 48.1% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 52 | 52 | $13,905 | $5,362 | 38.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 60 | 65 | $6,045 | $3,402 | 56.3% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Facility | 2021 | 29 | 29 | $4,060 | $1,969 | 48.5% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Facility | 2021 | 13 | 13 | $416.00 | $283.91 | 68.2% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 234 | 255 | $56,350 | $21,459 | 38.1% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 101 | 101 | $35,855 | $12,936 | 36.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 120 | 129 | $18,060 | $8,080 | 44.7% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Facility | 2020 | 51 | 51 | $13,515 | $4,988 | 36.9% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 18 | 18 | $8,555 | $3,229 | 37.7% |
About Dr. Sanjeev Vaishnavi, MD
Dr. Sanjeev Vaishnavi, MD is a Neurology healthcare provider based in Philadelphia, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/13/2010. The National Provider Identifier (NPI) number assigned to this provider is 1669790754.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sanjeev Vaishnavi, MD has received a total of $9,369 in payments from pharmaceutical and medical device companies, with $6,695 received in 2023. These payments were reported across 15 transactions from 3 companies. The most common payment nature is "Consulting Fee" ($4,725).
As a Medicare-enrolled provider, Vaishnavi has provided services to 2,531 Medicare beneficiaries, totaling 2,720 services with total Medicare billing of $258,529. Data is available for 4 years (2020–2023), covering 29 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Philadelphia, PA
- Active Since 05/13/2010
- Last Updated 08/03/2015
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1669790754
Products in Payments
- CNP520 (Drug) $601.29
- Leqembi (Drug) $40.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Philadelphia
Dr. Thomas Leist, M.d, M.D
Neurology — Payments: $2.0M
Neurology $2.0M
Dr. Daniel Kremens, M.d., J.d, M.D., J.D
Neurology — Payments: $1.9M
Neurology $1.9M
Dr. Jill Giordano Farmer, Do, DO
Neurology — Payments: $1.1M
Neurology $1.1M
Dr. Stephen Silberstein, M.d, M.D
Neurology — Payments: $936,801
Neurology $936,801
Amit Bar-Or
Neurology — Payments: $904,147
Neurology $904,147
Dr. Stephanie Nahas-Geiger, M.d, M.D
Neurology — Payments: $828,295
Neurology $828,295